Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies
Abstract The Global Diabetes Compact was launched by the World Health Organization in April 2021 with one of its important goals to increase the accessibility and affordability of life-saving medicine—insulin. The rising prevalence of diabetes worldwide is bound to escalate the demand for recombinan...
Main Authors: | Yin Yin Siew, Wei Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-07-01
|
Series: | Bioresources and Bioprocessing |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40643-021-00419-w |
Similar Items
-
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
by: Irina A. Proskurina, et al.
Published: (2016-07-01) -
Biphasic Insulin Analogues in Type 2 Diabetes: Expert Panel Recommendations
by: Sema Akalın, et al.
Published: (2011-09-01) -
Treatment of Type 2 Diabetes with Biphasic Insulin Analogues
by: Ali A. Rizvi
Published: (2016-10-01) -
Insulin analogues and cancer: a note of caution
by: Joseph A.M.J.L. eJanssen, et al.
Published: (2014-05-01) -
Health Technology Assessment on Insulin Analogues: the Rapid Review of Second Type Studies
by: A Oliyaeemanesh, et al.
Published: (2012-07-01)